{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T08:26:13Z","timestamp":1768983973994,"version":"3.49.0"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["15K19561"],"award-info":[{"award-number":["15K19561"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005694","name":"Hori Sciences and Arts Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005694","id-type":"DOI","asserted-by":"publisher"}]},{"name":"YOKOYAMA Foundation for Clinical Pharmacology"},{"name":"Nagao Memorial Fund"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","cancerletters.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.canlet.2018.06.027","type":"journal-article","created":{"date-parts":[[2018,6,23]],"date-time":"2018-06-23T07:41:23Z","timestamp":1529739683000},"page":"117-130","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Novel combined Ato-C treatment synergistically suppresses proliferation of Bcr-Abl-positive leukemic cells in vitro and in vivo"],"prefix":"10.1016","volume":"433","author":[{"given":"Md","family":"Wahiduzzaman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6296-2921","authenticated-orcid":false,"given":"Akinobu","family":"Ota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sivasundaram","family":"Karnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiro","family":"Hanamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shohei","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo","family":"Kanasugi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Md Lutfur","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshinori","family":"Hyodo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Konishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinobu","family":"Tsuzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiyoshi","family":"Takami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitaka","family":"Hosokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2018.06.027_bib1","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(13)62120-0","article-title":"Chronic myeloid leukaemia","volume":"385","author":"Apperley","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2018.06.027_bib2","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Faderl","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2018.06.027_bib3","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia","volume":"340","author":"Sawyers","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2018.06.027_bib4","first-page":"101","article-title":"BCR-ABL tyrosine kinase is autophosphorylated or transphosphorylates P160 BCR on tyrosine predominantly within the first BCR exon","volume":"8","author":"Liu","year":"1993","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2018.06.027_bib5","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2018.06.027_bib6","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Canc. Cell"},{"key":"10.1016\/j.canlet.2018.06.027_bib7","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2018.06.027_bib8","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory Philadelphia chromosome-positive leukemias","volume":"367","author":"Cortes","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2018.06.027_bib9","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","article-title":"Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy","volume":"109","author":"Hochhaus","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2018.06.027_bib10","first-page":"5995","article-title":"Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR\/ABL-positive cell line","volume":"62","author":"Ricci","year":"2002","journal-title":"Canc. Res."},{"key":"10.1016\/j.canlet.2018.06.027_bib11","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood.V99.9.3472","article-title":"High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR\/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance","volume":"99","author":"Branford","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2018.06.027_bib12","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.canlet.2018.06.027_bib13","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Canc. Cell"},{"key":"10.1016\/j.canlet.2018.06.027_bib14","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/sj.leu.2404318","article-title":"Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate","volume":"20","author":"Jabbour","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2018.06.027_bib15","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/sj.leu.2402889","article-title":"Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back","volume":"17","author":"von Bubnoff","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2018.06.027_bib16","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1182\/blood-2002-09-2780","article-title":"Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment","volume":"101","author":"Bhatia","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2018.06.027_bib17","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/leu.2012.85","article-title":"Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)","volume":"26","author":"Hanfstein","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2018.06.027_bib18","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1053\/j.seminhematol.2010.06.008","article-title":"Stem cell transplant for chronic myeloid leukemia in the imatinib era","volume":"47","author":"Radich","year":"2010","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.canlet.2018.06.027_bib19","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1182\/blood-2006-11-055186","article-title":"Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia","volume":"109","author":"Hehlmann","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2018.06.027_bib20","doi-asserted-by":"crossref","first-page":"38022","DOI":"10.18632\/oncotarget.16723","article-title":"Combination therapy in combating cancer","volume":"8","author":"Bayat Mokhtari","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2018.06.027_bib21","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/nrc887","article-title":"How acute promyelocytic leukaemia revived arsenic","volume":"2","author":"Zhu","year":"2002","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.canlet.2018.06.027_bib22","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1182\/blood-2007-07-102798","article-title":"Acute promyelocytic leukemia: from highly fatal to highly curable","volume":"111","author":"Wang","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2018.06.027_bib23","first-page":"3297","article-title":"Consolidation therapy of arsenic trioxide alternated with chemotherapy achieves remarkable efficacy in newly diagnosed acute promyelocytic leukemia","volume":"8","author":"Liu","year":"2015","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.canlet.2018.06.027_bib24","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1182\/blood-2005-06-2318","article-title":"Coordination of intrinsic, extrinsic, and endoplasmic reticulum-mediated apoptosis by imatinib mesylate combined with arsenic trioxide in chronic myeloid leukemia","volume":"107","author":"Du","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2018.06.027_bib25","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/sj.leu.2402104","article-title":"Co-treatment with As2O3 enhances selective cytotoxic effects of STI-571 against Brc-Abl-positive acute leukemia cells","volume":"15","author":"Porosnicu","year":"2001","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2018.06.027_bib26","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s13402-014-0167-7","article-title":"Combined arsenic trioxide-cisplatin treatment enhances apoptosis in oral squamous cell carcinoma cells","volume":"37","author":"Nakaoka","year":"2014","journal-title":"Cell. Oncol."},{"key":"10.1016\/j.canlet.2018.06.027_bib27","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1111\/j.1349-7006.2009.01340.x","article-title":"Arsenic trioxide and cisplatin synergism increase cytotoxicity in human ovarian cancer cells: therapeutic potential for ovarian cancer","volume":"100","author":"Zhang","year":"2009","journal-title":"Canc. Sci."},{"key":"10.1016\/j.canlet.2018.06.027_bib28","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/blood.V92.10.3780","article-title":"Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr\/abl-transduced bone marrow","volume":"92","author":"Pear","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2018.06.027_bib29","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv. Enzym. Regul."},{"issue":"58","key":"10.1016\/j.canlet.2018.06.027_bib30","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.canlet.2018.06.027_bib31","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.taap.2013.10.012","article-title":"Arsenic augments the uptake of oxidized LDL by upregulating the expression of lectin-like oxidized LDL receptor in mouse aortic endothelial cells","volume":"273","author":"Hossain","year":"2013","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.canlet.2018.06.027_bib32","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/cas.12053","article-title":"Arsenic trioxide prevents nitric oxide production in lipopolysaccharide -stimulated RAW 264.7 by inhibiting a TRIF-dependent pathway","volume":"104","author":"Takahashi","year":"2013","journal-title":"Canc. Sci."},{"key":"10.1016\/j.canlet.2018.06.027_bib33","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1038\/nprot.2013.143","article-title":"Genome engineering using the CRISPR-Cas9 system","volume":"8","author":"Ran","year":"2013","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.canlet.2018.06.027_bib34","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s10238-013-0233-x","article-title":"Anticancer effect of arsenic trioxide on cholangiocarcinoma: in vitro experiments and in vivo xenograft mouse model","volume":"14","author":"Kim","year":"2014","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.canlet.2018.06.027_bib35","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.3892\/ol.2017.6646","article-title":"Tumour growth-suppressive effect of arsenic trioxide in squamous cell lung carcinoma","volume":"14","author":"Leung","year":"2017","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.canlet.2018.06.027_bib36","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jphs.2015.08.009","article-title":"EphB4 inhibitor overcome the acquired resistance to cisplatin in melanomas xenograft model","volume":"129","author":"Yang","year":"2015","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.canlet.2018.06.027_bib37","doi-asserted-by":"crossref","first-page":"19265","DOI":"10.3390\/ijms151019265","article-title":"Effects of SC-560 in combination with cisplatin or taxol on angiogenesis in human ovarian cancer xenografts","volume":"15","author":"Li","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2018.06.027_bib38","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1038\/sj.bjc.6605642","article-title":"Committee of the National Cancer Research Institute. Guidelines for the welfare and use of animals in cancer research","volume":"102","author":"Workman","year":"2010","journal-title":"Br. J. Canc."},{"key":"10.1016\/j.canlet.2018.06.027_bib39","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1158\/1535-7163.MCT-05-0101","article-title":"T315I-mutated Bcr-Abl in chronic myeloid leukemia and imatinib: insights from a computational study","volume":"4","author":"Pricl","year":"2005","journal-title":"Mol. Canc. Therapeut."},{"key":"10.1016\/j.canlet.2018.06.027_bib40","first-page":"136","article-title":"Co-transfection of p16(INK4a) and p53 genes into the K562 cell line inhibits cell proliferation","volume":"87","author":"Rui","year":"2002","journal-title":"Haematologica"},{"key":"10.1016\/j.canlet.2018.06.027_bib41","doi-asserted-by":"crossref","first-page":"6056","DOI":"10.1158\/0008-5472.CAN-13-0453","article-title":"FOXO transcription factors control E2F1 transcriptional specificity and apoptotic function","volume":"73","author":"Shats","year":"2013","journal-title":"Canc. Res."},{"key":"10.1016\/j.canlet.2018.06.027_bib42","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","article-title":"BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet","volume":"118","author":"Soverini","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2018.06.027_bib43","first-page":"247","article-title":"Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia","volume":"13","author":"Shuai","year":"1996","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2018.06.027_bib44","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/emmm.201000062","article-title":"Stat5 is indispensable for the maintenance of bcr\/abl-positive leukaemia","volume":"2","author":"Hoelbl","year":"2010","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.canlet.2018.06.027_bib45","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1182\/blood-2009-11-255232","article-title":"The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors","volume":"117","author":"Nelson","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2018.06.027_bib46","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2005-09-3732","article-title":"A MAPK\/HNRPK pathway controls BCR\/ABL oncogenic potential by regulating MYC mRNA translation","volume":"107","author":"Notari","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2018.06.027_bib47","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/0092-8674(92)90241-4","article-title":"Dominant negative MYC blocks transformation by ABL oncogenes","volume":"70","author":"Sawyers","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2018.06.027_bib48","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12943-015-0407-0","article-title":"BCR\/ABL1 and BCR are under the transcriptional control of the MYC oncogene","volume":"14","author":"Sharma","year":"2015","journal-title":"Mol. Canc."},{"key":"10.1016\/j.canlet.2018.06.027_bib49","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.3324\/haematol.2014.115691","article-title":"c-Myc inhibition decreases CIP2A and reduces BCR-ABL1 tyrosine kinase activity in chronic myeloid leukemia","volume":"100","author":"Lucas","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.canlet.2018.06.027_bib50","first-page":"7950","article-title":"Arsenic trioxide inhibits translation of mRNA of bcr-abl, resulting in attenuation of Bcr-Abl levels and apoptosis of human leukemia cells","volume":"63","author":"Nimmanapalli","year":"2003","journal-title":"Canc. Res."},{"key":"10.1016\/j.canlet.2018.06.027_bib51","first-page":"3409","article-title":"BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity","volume":"60","author":"Puccetti","year":"2000","journal-title":"Canc. Res."},{"key":"10.1016\/j.canlet.2018.06.027_bib52","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/ijc.24341","article-title":"Downregulation of the c-MYC target gene, peroxiredoxin III, contributes to arsenic trioxide-induced apoptosis in acute promyelocytic leukemia","volume":"125","author":"Vivas-Mejia","year":"2009","journal-title":"Int. J. Canc."},{"key":"10.1016\/j.canlet.2018.06.027_bib53","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1172\/JCI14064","article-title":"Arsenic inhibition of telomerase transcription leads to genetic instability","volume":"108","author":"Chou","year":"2001","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2018.06.027_bib54","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.1182\/blood-2005-10-4110","article-title":"Ilaria, STAT5 signaling is required for the efficient induction and maintenance of CML in mice","volume":"107","author":"Ye","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2018.06.027_bib55","doi-asserted-by":"crossref","first-page":"35631","DOI":"10.1074\/jbc.M005401200","article-title":"c-Abl has high intrinsic tyrosine kinase activity that is stimulated by mutation of the Src homology 3 domain and by autophosphorylation at two distinct regulatory tyrosines","volume":"275","author":"Brasher","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2018.06.027_bib56","doi-asserted-by":"crossref","first-page":"7137","DOI":"10.1038\/sj.onc.1205942","article-title":"Jak2 is involved in c-Myc induction by Bcr-Abl","volume":"21","author":"Xie","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2018.06.027_bib57","first-page":"2588","article-title":"Increase of cisplatin sensitivity by c-myc antisense oligodeoxynucleotides in a human metastatic melanoma inherently resistant to cisplatin","volume":"5","author":"Leonetti","year":"1999","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.canlet.2018.06.027_bib58","article-title":"Inhibition of c-Myc overcomes cytotoxic drug resistance in acute myeloid leukemia cells by promoting differentiation","volume":"9","author":"Pan","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2018.06.027_bib59","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1182\/blood-2009-10-248211","article-title":"High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia","volume":"117","author":"Warsch","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2018.06.027_bib60","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1242\/jcs.001222","article-title":"Dynamic FoxO transcription factors","volume":"120","author":"Huang","year":"2007","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.canlet.2018.06.027_bib61","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.1128\/MCB.01789-06","article-title":"Induction of Mxi1-SR alpha by FOXO3a contributes to repression of Myc-dependent gene expression","volume":"27","author":"Delpuech","year":"2007","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2018.06.027_bib62","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1038\/sj.emboj.7600279","article-title":"Myc-induced proliferation and transformation require Akt-mediated phosphorylation of FoxO proteins","volume":"23","author":"Bouchard","year":"2004","journal-title":"EMBO J."},{"key":"10.1016\/j.canlet.2018.06.027_bib63","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1074\/jbc.M606669200","article-title":"FOXO3a induces differentiation of Bcr-Abl-transformed cells through transcriptional down-regulation of Id1","volume":"282","author":"Birkenkamp","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2018.06.027_bib64","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1002\/stem.1748","article-title":"The antiproliferative activity of kinase inhibitors in chronic myeloid leukemia cells is mediated by FOXO transcription factors","volume":"32","author":"Pellicano","year":"2014","journal-title":"Stem Cell."},{"key":"10.1016\/j.canlet.2018.06.027_bib65","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2131\/jts.41.105","article-title":"Arsenic acid inhibits proliferation of skin fibroblasts, and increases cellular senescence through ROS mediated MST1-FOXO signaling pathway","volume":"41","author":"Yamaguchi","year":"2016","journal-title":"J. Toxicol. Sci."},{"key":"10.1016\/j.canlet.2018.06.027_bib66","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1210\/en.2013-1179","article-title":"Inhibition of cisplatin-induced lipid catabolism and weight loss by ghrelin in male mice","volume":"154","author":"Garcia","year":"2013","journal-title":"Endocrinology"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383518304312?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383518304312?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T05:51:25Z","timestamp":1604469085000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383518304312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":66,"alternative-id":["S0304383518304312"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2018.06.027","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel combined Ato-C treatment synergistically suppresses proliferation of Bcr-Abl-positive leukemic cells in vitro and in vivo","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2018.06.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}